Analysts expect Protalix BioTherapeutics, Inc. to report revenue of 12.76 M for Q3 26, against a range of 12.13 M to 13.39 M. The most recent reported quarter, Q2 26, came in at 19.90 M, a 47.6% beat against the 13.48 M consensus.
| Metric | Q1 10 | Q2 10 | Q3 10 | Q4 10 | Q1 11 | Q2 11 | Q3 11 | Q4 11 | Q1 12 | Q2 12 | Q3 12 | Q4 12 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | 1.14 M | 1.14 M | 3.18 M | 1.18 M | 4.13 M | 760,000.00 | 1.13 M | 2.36 M | 3.86 M | 26.11 M | 3.72 M | 1.20 M | 17.96 M | 18.22 M | 10.11 M | 15.66 M | 17.85 M | 9.12 M | 33.75 M | 19.90 M | - | - | - | - | - | - | - | - | ||||||
| High Estimate | 1.75 M | 2.05 M | 2.66 M | 6.00 M | 6.18 M | 2.47 M | 2.67 M | 1.56 M | 1.29 M | 1.99 M | 3.49 M | 9.68 M | 18.35 M | 18.98 M | 22.21 M | 15.69 M | 20.07 M | 20.36 M | 11.52 M | 14.29 M | 13.39 M | 15.52 M | 14.89 M | 19.36 M | 13.09 M | 14.45 M | 12.53 M | 35.27 M | ||||||
| Low Estimate | 1.57 M | 1.69 M | 2.44 M | 5.09 M | 5.52 M | 2.09 M | 2.30 M | 1.41 M | 1.16 M | 1.70 M | 2.96 M | 8.22 M | 16.03 M | 16.72 M | 19.60 M | 14.60 M | 17.81 M | 17.98 M | 10.84 M | 12.67 M | 12.13 M | 14.61 M | 13.95 M | 17.24 M | 10.73 M | 12.80 M | 11.71 M | 29.69 M | ||||||
| Consensus Estimate | 1.66 M | 1.87 M | 2.55 M | 5.55 M | 5.85 M | 2.28 M | 2.49 M | 1.48 M | 1.23 M | 1.84 M | 3.23 M | 8.95 M | 17.19 M | 17.85 M | 20.91 M | 15.15 M | 18.94 M | 19.17 M | 11.18 M | 13.48 M | 12.76 M | 15.06 M | 14.42 M | 18.30 M | 11.91 M | 13.63 M | 12.12 M | 32.48 M |
Analysts expect Protalix BioTherapeutics, Inc. to report earnings per share of -0.02 for Q3 26, against a range of -0.02 to -0.02. The most recent reported quarter, Q2 26, came in at 0.05, a 600.0% beat against the -0.01 consensus.
| Metric | Q1 10 | Q2 10 | Q3 10 | Q4 10 | Q1 11 | Q2 11 | Q3 11 | Q4 11 | Q1 12 | Q2 12 | Q3 12 | Q4 12 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | -0.10 | -0.12 | -0.03 | -0.11 | -0.06 | -0.16 | -0.10 | -0.10 | -0.07 | 0.10 | -0.06 | -0.11 | 0.03 | 0.10 | -0.05 | 0.00 | 0.03 | -0.06 | 0.22 | 0.05 | - | - | - | - | - | - | - | - | ||||||
| High Estimate | -0.10 | -0.07 | -0.12 | -0.06 | -0.05 | -0.11 | -0.09 | -0.08 | -0.09 | -0.11 | -0.11 | -0.06 | 0.07 | 0.07 | 0.08 | 0.04 | 0.06 | 0.04 | -0.01 | -0.01 | -0.02 | -0.01 | 0.01 | 0.01 | -0.05 | -0.05 | 0.04 | 0.04 | ||||||
| Low Estimate | -0.10 | -0.09 | -0.12 | -0.06 | -0.07 | -0.13 | -0.09 | -0.10 | -0.11 | -0.11 | -0.13 | -0.08 | 0.05 | 0.07 | 0.08 | 0.04 | 0.06 | 0.04 | -0.01 | -0.01 | -0.02 | -0.01 | 0.01 | 0.01 | -0.05 | -0.07 | 0.04 | 0.04 | ||||||
| Consensus Estimate | -0.10 | -0.08 | -0.12 | -0.06 | -0.06 | -0.12 | -0.09 | -0.09 | -0.10 | -0.11 | -0.12 | -0.07 | 0.06 | 0.07 | 0.08 | 0.04 | 0.06 | 0.04 | -0.01 | -0.01 | -0.02 | -0.01 | 0.01 | 0.01 | -0.05 | -0.06 | 0.04 | 0.04 |
Pull Wall Street consensus for Protalix BioTherapeutics, Inc. (high, low and consensus estimates alongside reported actuals) into your own models and apps with the Business Quant Estimates API. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/estimates?ticker=PLX&mode=revenue&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/estimates"
params = {"ticker": "PLX", "mode": "revenue", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/estimates?ticker=PLX&mode=revenue&api_key=YOUR_API_KEY");
const data = await res.json();